Sonoma Pharmaceuticals
Update in progressSNOA (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Sonoma Pharmaceuticals, Inc. develops stabilized hypochlorous acid (HOCl) products for wound and eye care, skin care, oral and nasal care, podiatry, dermatology, and animal health worldwide. Its portfolio includes Microcyn line products for healing and disinfection, Lumacyn, Regenacyn, Reliefacyn, Gramaderm, Epicyn, Levicyn, Celacyn, Pediacyn, Ocucyn, Ocudox, Sinudox, Microcyn60, Podiacyn, MicrocynAH, MicrocynVS, Nanocyn, Acuicyn, MucoClyns, and Endocyn. Formerly Oculus Innovative Sciences; based in Boulder, CO.
Company score
- Sentiment
- -0.05
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.00
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMs. Amy M. Trombly Esq., J.D.
- Founded1999
- Employees10
- Websitesonomapharma.com
Identifiers
- ISINUS83558L2043
- FIGIBBG000M75YR0
- LEI54930008C5Z4F02SWO71
- CUSIP67575P108
- CIK0001367083